Hikma Pharmaceuticals Plc Hikma appoints new President of Injectables (7127I)
09 Agosto 2023 - 1:00AM
UK Regulatory
TIDMHIK
RNS Number : 7127I
Hikma Pharmaceuticals Plc
09 August 2023
Hikma appoints new President of Injectables business
London, 9 August 2023 - Hikma Pharmaceuticals PLC and its
subsidiaries ('Hikma' or 'Group'), the multinational pharmaceutical
company, announce that Dr. Bill Larkins has been appointed
President of its Injectables business, effective 1 September 2023.
Bill will be based in the US and report to Riad Mishlawi in his new
role as Hikma's Chief Executive Officer.
Bill has extensive experience in the sterile injectable generic
market. He was previously Chief Executive Officer of Custopharm,
which was acquired by Hikma in 2022 and has since been Hikma's
Senior Vice President, R&D, Injectables.
During his career, Bill has held senior leadership roles at
leading injectable pharmaceutical companies including Bedford
Laboratories and ESI Lederle/Baxter. He also played a significant
role at Schein Pharmaceuticals' Steris Laboratories in Phoenix and
at Amylin Pharmaceuticals, where he worked on the development of
complex injectable medicines.
Commenting on the appointment, Riad Mishlawi, President of
Injectables / CEO-elect said: "Bill's exceptional leadership
skills, vast expertise, and successful track record make him the
ideal person to lead our Injectables team. Over the next few years,
we have a tremendous opportunity to further expand Hikma's position
as a market-leading manufacturer and supplier of generic injectable
medicines. I look forward to working with Bill in his new
role."
Dr. Bill Larkins added: "This is a very exciting opportunity for
me to lead a highly talented team, who have been growing and
developing this business so successfully over the years. I am
confident that we can continue to leverage our differentiated
R&D pipeline, capacity expansion projects and new businesses to
further enhance our position as one of the leading providers of
injectable medicines across our geographies."
- ENDS -
Hikma (Investors):
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795
Associate Director, Investor Relations 896738
Layan Kalisse +44 (0)20 7399 2788/ +44 (0)7970
Senior Associate, Investor Relations 709912
Teneo (Press):
Charles Armitstead / Rob Yates +44 (0)7703 330269/ +44 (0)7715 375443
About Hikma:
Hikma helps put better health within reach every day for
millions of people around the world. For more than 45 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across North America, the Middle East
and North Africa (MENA) and Europe, and we use our unique insight
and expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,700
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and
BBB-/positive Fitch)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAVVLFBXVLBBBX
(END) Dow Jones Newswires
August 09, 2023 02:00 ET (06:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024